Собственный опыт применения двойной анти-HER2 терапии при раке внутрипеченочных желчных протоков

Рак билиарного тракта является редким и одним из наиболее агрессивных злокачественных новообразований. Основным методом радикального лечения является хирургический. Однако, только у 1/3 больных возможно применение данного подхода, остальные же пациенты имеют нерезектабельный, местно-распространенный или уже метастатический процесс. Лечебной тактикой данной группы больных является системная лекарственная противоопухолевая терапия. В данной статье мы представляем описание клинического случая эффективного лечения пациента с распространенной внутрипеченочной холангиокарциномой с использованием не только стандартных цитостатиков, но и современных таргетных препаратов.

1. Buettner S., van Vugt J.L., Ijzermans J.N., Groot Koerkamp B. Intrahepatic cholangiocarcinoma: currentperspectives. OncoTargetsTher. 2017; 10: 1131–1142. DOI: 10.2147/OTT.S93629.

2. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–477.https://doi.org/10.1016/j.jhep.2003.11.030

3. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD et al. Rising trends in cholangiocarcinoma: is the ICD classifi cation system misleading us? J Hepatol. 2012;56(4):848–854.https://doi.org/10.1016/j.jhep.2011.11.015

4. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci. 2010;25(7):1011–1016. https://doi.org/10.3346/jkms.2010.25.7.1011

5. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, Vecchia CL. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24(6):1667–1674. https://doi.org/10.1093/annonc/mds652

6. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–184. https://doi.org/10.1002/hep.24351

7. Buettner S., van Vugt J.L., Ijzermans J.N., Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. OncoTargetsTher. 2017; 10: 1131–1142. DOI: 10.2147/OTT.S93629.

8. Гурмиков Б. Н., Коваленко Ю. А., Пайчадзе А. А., Маринова Л. А., Грицкевич А. А., Чжао А.В. Отдаленные результаты хирургического лечения внутрипеченочного холангиоцеллюлярного рака взависимости от мутационного статуса опухоли. Онкология. Журналим. П.А. Герцена. 2021;10(6):6–13. https://doi.org/10.17116/onkolog2021100616

9. Valle J., Wasan H., Palmer D. H., Cunningham D., Anthoney A., Maraveyas A. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281. https://doi.org/10.1056/NEJMoa0908721

10. Oh D.Y., He A.R., Qin S., Chen L., Okusaka T., Vogel A. et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(Suppl. 4):378. https://doi.org/10.1200/JCO.2022.40.4_suppl.378.

11. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 3;401(10391):1853–1865. doi: 10.1016/S0140–6736(23)00727-4.

12. Савченко ИВ, Бредер ВВ, Стилиди ИС, Лактионов КК, Кудашкин НЕ, Егорова АВ, Чулкова СВ. Вторая линия лекарственной терапии билиарного рака. Медицинский Совет. 2022;(22):136–147. https://doi.org/10.21518/2079–701X-2022-16-22-136-147

13. Weinberg BA, Xiu J, Lindberg MR, Shields AF, Hwang JJ, Poorman K, Salem ME, Pishvaian MJ, Holcombe RF, Marshall JL, Morse MA. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncology. 2019;10(4):652–662.https://doi.org/10.21037/jgo.2018.08.18

14. Ma B, Meng H, Tian Y, Wang Y, Song T, Zhang T, Wu Q, Cui Y, Li H, Zhang W, Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC cancer. 2020;20(1):318.

15. Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, et al. Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. CancerDiscov. 2017;7(10):1116–1135. https://doi.org/10.1158/2159–8290.CD-17–0368

16. Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: Potential impact of genomic studies on clinical management. Z Gastroenterol. 2017;55(6):575–581. https://doi.org/10.1055/s-0043–102581

17. Goeppert B, Frauenschuh L, Renner M, et al. BRAF V600E-specifi c immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. ModPathol. 2014;27(7):1028–1034. https://doi.org/10.1038/modpathol.2013.206

18. Chen MH, Chiang KC, Cheng CT, Huang SC, Chen YY, Chen TW, Yeh TS, Jan YY, Wang HM, Weng JJ, Chang PM, Liu CY, Li CP, Chao Y, Chen MH, Huang CY, Yeh CN. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget. 2014;5(9):2372–2389.https://doi.org/10.18632/oncotarget.1706

19. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58.https://doi.org/10.1186/s13045–015–0155-z

20. Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J ClinOncol. 2012;30(27): e271–273. https://doi.org/10.1200/JCO.2012.42.3061

21. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672. https://doi.org/10.1056/NEJMoa052306

22. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. https://doi.org/10.1016/s0140–6736(10)61121-x

23. Вторушин С. В., Крахмаль Н. В., Завалишина Л. Э., Кузнецова О.А., Москвина Л. В., Франк Г.А. Определение HER2-статуса карцином различных локализаций. Архив патологии. 2023;85(6):31–46.https://doi.org/10.17116/patol20238506131

24. Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profi les: Results From MyPathway, an Open-Label, Phase IIaMultiple Basket Study. J Clin Oncol. 2018;36(6):536–542. https://doi.org/10.1200/JCO.2017.75.3780

25. Javle, M., Borad, M. J., Azad, N. S., Kurzrock, R., Abou-Alfa, G. K., George, B., Hainsworth, J., Meric-Bernstam, F., Swanton, C., Sweeney, C. J., Friedman, C. F., Bose, R., Spigel, D. R., Wang, Y., Levy, J., Schulze, K., Cuchelkar, V., Patel, A., & Burris, H. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (My Pathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology, 22(9), 1290–1300. https://doi.org/10.1016/S1470–2045(21)00336-3

26. Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14). Lancet GastroenterolHepatol. 2023 Jan;8(1):56–65. doi: 10.1016/S2468–1253(22)00335-1. Epub 2022 Oct 31.

27. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA; DESTINY-Breast04 Trial Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022 Jul 7;387(1):9–20. doi: 10.1056/NEJMoa2203690.

28. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18;382(25):2419–2430. doi: 10.1056/NEJMoa2004413.

29. Bob T Li et al. Trastuzumab deruxtecan in patients with solid tumoursharbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol. 2024 Jun;25(6):707–719. doi: 10.1016/S1470–2045(24)00140-2.